50% OFF
MarketBeat All Access
Get 30 days free. Save 50% your first year.
  •  days
  •  Hours
  •  Minutes
  •  Seconds
×
S&P 500   3,647.29 (-0.21%)
DOW   29,134.99 (-0.43%)
QQQ   274.48 (+0.04%)
AAPL   151.76 (+0.66%)
MSFT   236.41 (-0.44%)
META   134.40 (-1.44%)
GOOGL   97.50 (-0.68%)
AMZN   114.41 (-0.64%)
TSLA   282.94 (+2.51%)
NVDA   124.13 (+1.51%)
NIO   17.19 (-2.44%)
BABA   77.87 (-1.32%)
AMD   67.17 (+1.31%)
T   15.73 (+0.38%)
MU   50.58 (+3.48%)
CGC   2.86 (+4.38%)
F   11.91 (-0.67%)
GE   64.47 (+0.19%)
DIS   95.85 (-2.31%)
AMC   7.45 (+9.08%)
PYPL   85.75 (+1.77%)
PFE   44.09 (+0.59%)
NFLX   224.36 (+0.13%)
S&P 500   3,647.29 (-0.21%)
DOW   29,134.99 (-0.43%)
QQQ   274.48 (+0.04%)
AAPL   151.76 (+0.66%)
MSFT   236.41 (-0.44%)
META   134.40 (-1.44%)
GOOGL   97.50 (-0.68%)
AMZN   114.41 (-0.64%)
TSLA   282.94 (+2.51%)
NVDA   124.13 (+1.51%)
NIO   17.19 (-2.44%)
BABA   77.87 (-1.32%)
AMD   67.17 (+1.31%)
T   15.73 (+0.38%)
MU   50.58 (+3.48%)
CGC   2.86 (+4.38%)
F   11.91 (-0.67%)
GE   64.47 (+0.19%)
DIS   95.85 (-2.31%)
AMC   7.45 (+9.08%)
PYPL   85.75 (+1.77%)
PFE   44.09 (+0.59%)
NFLX   224.36 (+0.13%)
S&P 500   3,647.29 (-0.21%)
DOW   29,134.99 (-0.43%)
QQQ   274.48 (+0.04%)
AAPL   151.76 (+0.66%)
MSFT   236.41 (-0.44%)
META   134.40 (-1.44%)
GOOGL   97.50 (-0.68%)
AMZN   114.41 (-0.64%)
TSLA   282.94 (+2.51%)
NVDA   124.13 (+1.51%)
NIO   17.19 (-2.44%)
BABA   77.87 (-1.32%)
AMD   67.17 (+1.31%)
T   15.73 (+0.38%)
MU   50.58 (+3.48%)
CGC   2.86 (+4.38%)
F   11.91 (-0.67%)
GE   64.47 (+0.19%)
DIS   95.85 (-2.31%)
AMC   7.45 (+9.08%)
PYPL   85.75 (+1.77%)
PFE   44.09 (+0.59%)
NFLX   224.36 (+0.13%)
S&P 500   3,647.29 (-0.21%)
DOW   29,134.99 (-0.43%)
QQQ   274.48 (+0.04%)
AAPL   151.76 (+0.66%)
MSFT   236.41 (-0.44%)
META   134.40 (-1.44%)
GOOGL   97.50 (-0.68%)
AMZN   114.41 (-0.64%)
TSLA   282.94 (+2.51%)
NVDA   124.13 (+1.51%)
NIO   17.19 (-2.44%)
BABA   77.87 (-1.32%)
AMD   67.17 (+1.31%)
T   15.73 (+0.38%)
MU   50.58 (+3.48%)
CGC   2.86 (+4.38%)
F   11.91 (-0.67%)
GE   64.47 (+0.19%)
DIS   95.85 (-2.31%)
AMC   7.45 (+9.08%)
PYPL   85.75 (+1.77%)
PFE   44.09 (+0.59%)
NFLX   224.36 (+0.13%)

Hold Pfizer Today With Catalysts for Further Growth Tomorrow

Hold Pfizer Today With Catalysts for Further Growth Tomorrow

There are short-term and long-term opportunities for PFE stock 

Pfizer (NYSE: PFE) stock is down 12% in 2022. Even though that’s better than the broader market, there are some concerns that Pfizer’s Covid-19 vaccine rally is winding down. But a recent announcement by the United States Food & Drug Administration (FDA) indicates that Pfizer may still have room to expand its lead in the Covid-19 vaccine race.  

However, the Covid-19 vaccine development is creating a longer-term catalyst for PFE stock. And the company has the balance sheet and scientific expertise to capitalize on this emerging growth opportunity.  

In this article, we’ll give you a brief outline of both catalysts so you can decide if an investment in PFE stock is right for your investment objectives.  

Pfizer May Surprise This Earnings Season 

Market watchers are advising investors to expect many analysts to revise their price targets lower during this earnings season. So it’s important to note that Pfizer recently received some news that may have the company updating its revenue and earnings forecast. This in turn could cause analysts to reconsider their forecasts for the stock.  

The specific news is that the FDA is expanding its Emergency Use Authorization (EUA) for Pfizer’s Covid-19 antiviral drug, Paxlovid. The expansion will pharmacists to prescribe the drug, removing a key barrier for patients in need of treatment.  

This means that it’s possible that Pfizer may be updating its full-year forecast for $22 billion in revenue from Paxlovid. And if that’s the case then it’s also possible that analysts may revisit the company’s price target either before or after Pfizer reports earnings on July 28.  


PFE Stock Has More Going For It Than Covid-19 Vaccines 

One of the winners in the Covid-19 pandemic was messenger ribonucleic acid (mRNA) technology. As Pfizer writes on their website, mRNA “is a molecule that contains the instructions or recipe that directs the cells to make a protein using its natural machinery.” 

Pfizer is one of the companies leading the way at using mRNA technology to take advantage of our body’s natural protein-making abilities to make molecules to help prevent or treat diseases. And the Covid-19 vaccines from Pfizer and Moderna (NASDAQ: MRNA) are the first examples of mRNA technology receiving approval by the Food & Drug Administration (FDA).  

The significance of this is that now the company can begin to expand upon the ability of mRNA technology. Currently that means more vaccines targeted to other infectious diseases such as influenza or shingles. However, in the future it may be used to treat other diseases such as cancer. And, via the company’s partnership with Beam Therapeutics (NASDAQ: BEAM), Pfizer is working to develop mRNA technology as an approach to gene editing.  

Building On Its Fundamental Strength 

To make a long story short, we’re entering a world of custom medicine and Pfizer is well positioned to take a leadership role. One reason for that is the significant cash balance that the company has built up through the success of its Covid-19 vaccines.  

In 2021, the company generated free cash flow of $29.86 billion dollars. And Pfizer’s total cash and short-term investments are at $31.07 billion, its highest level ever. With that level of strength, it’s a near certainty that Pifzer will increase its dividend for the 13th consecutive year sometime later in 2022. And as of this writing, PFE stock is trading at an appealing price-to-earnings (P/E) ratio of just under 12 times earnings.  

With that said, the long-term growth that Pfizer may deliver is years away. However, the company offers a strong balance sheet, stable earnings, a growing dividend, and the potential for significant growth with mRNA technology. Pfizer is a company to watch closely as it gets ready to report earnings.  

Companies Mentioned in This Article

CompanyMarketRank™Current PricePrice ChangeDividend YieldP/E RatioConsensus RatingConsensus Price Target
Pfizer (PFE)
3.2484 of 5 stars
$44.09+0.6%3.63%8.63Moderate Buy$57.00
Moderna (MRNA)
2.6551 of 5 stars
$122.23+2.1%N/A3.73Hold$211.08
Beam Therapeutics (BEAM)
1.547 of 5 stars
$48.41+4.0%N/A-14.24Moderate Buy$87.67
Compare These Stocks  Add These Stocks to My Watchlist 

Should you invest $1,000 in Pfizer right now?

Before you consider Pfizer, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pfizer wasn't on the list.

While Pfizer currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Chris Markoch

About Chris Markoch

Contributing Author: Retirement, Individual Investing

Chris Markoch is a freelance financial copywriter with over five years of experience covering various aspects of the financial markets. You may find his writing a little different than other stock articles you’ve read. And that’s OK with him. Chris doesn’t have a traditional finance background. What he does bring to the table is a strong business and marketing background having worked for agencies that serviced Fortune 500 companies. With that in mind, he isn’t overly impressed with what companies say, and more focused on what they do. And because buyer behavior dictates so much of what happens with a stock, Chris always keeps the end consumer close in mind. Chris has been writing for MarketBeat since 2018.

Contact Chris Markoch via email at CTMarkoch@msn.com.
Free Email Newsletter

Complete the form below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter:

Most Read This Week

Recent Articles

Search Headlines:

Latest PodcastFed Raises Rates: 3 Stocks to Watch Newmont Mining, Walmart, AMC

Axel Merk, President and CIO of Merk Investments has three very different stocks he frames within the current market and economic conditions.

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.